Stock Market Reviews

Read and share opinions on RARE (Ultragenyx Pharmaceutical Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
  Dec 30, 2025
• Company News for Dec 30, 2025
  Dec 30, 2025
• Top Midday Decliners
  Dec 29, 2025
• Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
  Dec 29, 2025
• Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
  Dec 29, 2025
• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  Dec 19, 2025
• Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound
  Dec 14, 2025
• Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?
  Dec 11, 2025
• Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
  Dec 4, 2025

RARE News

• Top Midday Decliners
  Ultragenyx Pharmaceutical (RARE) said Monday its phase 3 studies of setrusumab to treat osteogenesis
  Dec 29, 2025
• Sector Update: Health Care Stocks Edge Lower Monday Afternoon
  Health care stocks edged down Monday afternoon, with the NYSE Health Care Index and the State Street
  Dec 29, 2025
• Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
  Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index fractionally hi
  Dec 29, 2025
• Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
  Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improvements in bone mineral density with strong statistical significance LONDON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases, today announced results from the Phase 3 ORBIT and C
  Dec 29, 2025
• Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
  Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of improvements in bone mineral density with strong statistical significance The Company will implement significant expense reductions NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setr
  Dec 29, 2025
• Top Midday Stories: DigitalBridge to Be Acquired by SoftBank; Ultragenyx's Brittle Bone Disease Drug Studies Miss Primary Endpoints
  All three major US stock indexes were down in late-morning trading Monday to kick off the final few
  Dec 29, 2025
• Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
  A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.
  Dec 29, 2025
• These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More
  Nvidia and Tesla shares fall, DigitalBridge jumps after SoftBank agrees to acquire the data-center investment firm, and Newmont slumps as precious metals prices tumble.
  Dec 29, 2025
• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 13,144 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Em
  Dec 19, 2025
• Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound
  Ultragenyx Pharmaceutical stock reacts to shifting sentiment Ultragenyx Pharmaceutical (RARE) has been quietly recalibrating investor expectations, with the stock up about 10% over the past month even as the past year remains firmly negative. See our latest analysis for Ultragenyx Pharmaceutical. That recent 30 day share price return of around 9.5 percent, on top of a roughly 25 percent gain over 90 days, suggests momentum is rebuilding even though the one year total shareholder return is...
  Dec 14, 2025
• Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?
  Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a $103 price target. The positive stance aligns with a Consensus Strong Buy rating from 13 Wall Street analysts, […]
  Dec 11, 2025
• Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
  Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025
• Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
  DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
  Dec 3, 2025
• Tactical Resources Announces Share Consolidation
  VANCOUVER, BC / ACCESS Newswire / December 3, 2025 / Tactical Resources Corp. (TSX.V: RARE)(OTC PINK:USREF) ("Tactical" or the "Company"), a mineral exploration and development company, announces that, in connection with the Company's previously announced ...
  Dec 3, 2025
• Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025?
  Curious whether Ultragenyx Pharmaceutical is attractively priced or overpriced in today's market? There are some intriguing signals in the numbers that investors may want to explore further. The stock has moved up 3.5% in the past week, although it is down 1.2% over the past month and 27.0% in the last year. This points to recent volatility and shifting market sentiment. News about FDA regulatory updates and late-stage clinical developments has shaped investor expectations, with increased...
  Nov 30, 2025
• Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest
  Ultragenyx Pharmaceutical (RARE) shares recently showed some movement as the company reported 15% year-over-year revenue growth for the third quarter and reaffirmed a strong outlook for the year. The company’s leadership is also set to engage with investors at several healthcare conferences, which demonstrates ongoing commitment and transparency. See our latest analysis for Ultragenyx Pharmaceutical. After a choppy year, Ultragenyx’s stock has regained some momentum lately with a 16% share...
  Nov 30, 2025
• Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook
  Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24, Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and maintained an Overweight rating on the shares. The firm lowered its price target following analysis of the setrusumab COSMIC study, but […]
  Nov 28, 2025
• Ultragenyx to Participate in Investor Conferences in December
  NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in two upcoming investor conferences. Citi’s 2025 Global Healthcare Conference (Miami, FL) Tuesday, December 2, 2025, Eric Crombez, M.D., Chief Medical Officer will participate in a fireside chat. 8th Annual Evercore ISI Health
  Nov 24, 2025
• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 18,180 restricted stock units of the company’s common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl
  Nov 21, 2025
• Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT
  Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 15 stocks set to explode in 2026. On November 5, 2025, analyst Maxwell Skor from Morgan Stanley reaffirmed his “Buy” rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) with a $55 price target. The analyst’s bullish stance stemmed from Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) strong financial position, alongside its pivotal […]
  Nov 11, 2025
• Ultragenyx Pharmaceutical (RARE): Profit and Revenue Growth Forecasts Highlight Deep Valuation Gap Heading Into Earnings
  Ultragenyx Pharmaceutical (RARE) remains unprofitable, with net losses expanding at an average annual rate of 14.8% over the past five years. Even as the company’s profit margin has yet to turn positive, forecasts are calling for a sharp turnaround with projected earnings growth of 81.24% per year and revenue expected to rise by 28.5% per year, well ahead of the broader US market’s 10.5% forecast. With these growth expectations and no major risk warnings flagged, investors are focused on the...
  Nov 6, 2025
• Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
  RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
  Nov 5, 2025
• Ultragenyx Pharmaceutical Inc (RARE) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ...
  Ultragenyx Pharmaceutical Inc (RARE) reports a 15% revenue increase in Q3 2025, while navigating a net loss and high operating expenses.
  Nov 5, 2025
• Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings
  The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
  Nov 4, 2025
• Ultragenyx: Q3 Earnings Snapshot
  RARE) on Tuesday reported a loss of $180.4 million in its third quarter. The Novato, California-based company said it had a loss of $1.81 per share. The results fell short of Wall Street expectations.
  Nov 4, 2025
• Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
  Ultragenyx (RARE) delivered earnings and revenue surprises of -47.15% and -4.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025
• Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
  Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a
  Nov 4, 2025
• Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
  Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the next stage of growth NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel p
  Nov 4, 2025
• Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
  NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an investigational antisense oligonucleotide (ASO) for Angelman syndrome (AS). Data from the Aurora study will expand the population of Angelman patients treated to include both younger and older patients and those with other non-deletion AS genotypes not
  Oct 30, 2025
• Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025
• Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
  Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 28, 2025
• Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
  NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025. The live and replayed webcast of the call will be available thr
  Oct 28, 2025
• Ultragenyx Pharmaceutical (RARE): Assessing Valuation as Shares Surge 21% in Past Month
  Ultragenyx Pharmaceutical (RARE) shares have seen some movement lately, attracting attention from investors curious about the company’s direction. The stock has delivered a 21% gain over the past month, showing stronger performance compared to previous quarters. See our latest analysis for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical’s strong 21.4% gain over the past month follows a steady run of positive momentum, which contrasts with its challenging longer-term performance. While...
  Oct 28, 2025
• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl
  Oct 24, 2025
• Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?
  DBV Technologies (DBVT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 17, 2025
• Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE)
  Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks with high potential. On October 3, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $79.00. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $166 million in total revenue for fiscal Q2 2025, with […]
  Oct 8, 2025
• Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress
  Ultragenyx Pharmaceutical (RARE) drew attention after recent regulatory wins, including FDA Breakthrough Therapy designation for GTX-102 and a new label expansion for Evkeeza. Both developments highlight the company’s continued progress within rare disease markets. See our latest analysis for Ultragenyx Pharmaceutical. Alongside these milestones, Ultragenyx has welcomed a new chief business officer and seen institutional investors significantly increase their stakes, all in the context of...
  Oct 3, 2025
• How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy?
  Ultragenyx Pharmaceutical Inc. recently appointed Eric Olson as chief business officer and executive vice president, following the planned retirement of Thomas Kassberg after 14 years with the company, effective September 22, 2025. Olson’s nearly twenty years of biopharma business development experience, especially in rare diseases and high-value collaborations, marks a significant addition to Ultragenyx’s leadership during a period of ongoing pipeline and commercial expansion. We’ll now...
  Oct 2, 2025
• Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
  Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns […]
  Oct 2, 2025

RARE Reviews

• ManiaBroker

  Dec 29, 2025

  $RARE Investing in this stock is a bit like hunting for unicorns – elusive and magical, but hey, dreams come true sometimes!

  Sell

• GainVector

  Dec 29, 2025

  $RARE Specializing in rare diseases, this pharmaceutical company is on the forefront of addressing critical health challenges. Their commitment to innovation and patient-centric solutions highlights their role in improving lives.

  Buy

• TendieTitan

  Dec 29, 2025

  $RARE Fighting rare diseases? Now that’s a mission worthy of a superhero. If only they could make my awkwardness disappear too!

  Buy

• StockNova

  Dec 29, 2025

  $RARE As a leader in rare disease therapies, this organization continues to push the boundaries of biotechnology. Its pipeline of promising treatments highlights its commitment to addressing unmet medical needs, fueling optimism for future advancements.

  Buy

• DividendDegen

  Dec 28, 2025

  $RARE This one's got that unicorn magic, hard to find but worth the chase!

  Buy

• TheQuantEdge

  Dec 27, 2025

  $RARE The volatility here is intense! Every development feels like a ticking clock, and you're left wondering if it's a cause for celebration or panic.

  Sell

• CandleBinary

  Dec 27, 2025

  $RARE Concentrating on rare diseases, this company's innovative therapies have the potential to address significant unmet medical needs. Their commitment to research and development could lead to breakthroughs that resonate strongly in the healthcare community.

  Buy

• TheFiscalShade

  Dec 27, 2025

  $RARE This joint's got the potential to blow up, keep an eye on it!

  Buy

• GammaSlayer

  Dec 27, 2025

  $RARE Their innovation feels rarer than their products.

  Sell

• BullishSniper

  Dec 27, 2025

  $RARE This stock is like finding a unicorn – mythical and hard to catch, but totally worth the chase if you manage to snag one!

  Buy

• CashKiller

  Dec 26, 2025

  $RARE Not rare enough to stand out in the crowded biotech field.

  Sell

• PaperHandsGone

  Dec 25, 2025

  $RARE Got that one-of-a-kind flair, don’t sleep on this gem!

  Buy

• TradeSaber

  Dec 24, 2025

  $RARE Playing in the rare disease space, but may need some extra push to shine.

  Sell

• RiskVandal

  Dec 23, 2025

  $RARE More like rare failure; can't believe people still fall for this.

  Sell

• MarketPulseX

  Dec 23, 2025

  $RARE Dedicated to the development of treatments for rare diseases, this company is making significant strides in an underserved market, indicating a unique potential for impact.

  Buy

• WallStreetBandit

  Dec 23, 2025

  $RARE Rarely worth looking at, even less often profitable.

  Sell

• BearFighter

  Dec 22, 2025

  $RARE Feel free to chase rarity, but don’t expect results.

  Sell

• AlphaRogue

  Dec 22, 2025

  $RARE This company's got more rare finds than a kid's sock drawer! Who knew pharmaceuticals could be so exclusive?

  Buy

• YieldMyth

  Dec 22, 2025

  $RARE Chasing rare finds, feelin' like a treasure hunt!

  Buy

• QuantumBroker

  Dec 22, 2025

  $RARE Pharmaceutical innovation is a double-edged sword—could this stock be the next lifesaver or just another disappointment? The anticipation is nerve-wracking!

  Buy

• CryptoCobra

  Dec 22, 2025

  $RARE This pharmaceutical company is like a unicorn — rare and magical, but hopefully not too mysterious when it comes to profits!

  Sell

• BullishBard

  Dec 21, 2025

  $RARE They’re like the unicorn of pharmaceuticals—focusing on the cool stuff that only the really brave try.

  Buy

• StonkDestroyer

  Dec 21, 2025

  $RARE Just another biotech chasing after shadows.

  Sell

• TradeNova

  Dec 21, 2025

  $RARE Pharma’s a wild ride, but this one’s lookin’ like a game changer!

  Buy

• EarningsEcho

  Dec 20, 2025

  $RARE This company might just be the unicorn of the stock market—rare gems that make you feel like you’re holding a ticket to the magical land of profits!

  Buy

• TradeNinja

  Dec 20, 2025

  $RARE With science on their side, they’re like the superheroes of medicine! Who doesn't want a bit of pharmaceutical magic in their life?

  Buy

• TheEquityEdge

  Dec 19, 2025

  $RARE The focus on rare diseases offers a niche opportunity in the pharmaceutical space, and ongoing collaborations with research institutions may enhance its ability to deliver unique therapies. Investors may find its mission compelling.

  Buy

• ChartPhantom

  Dec 19, 2025

  $RARE Like finding a unicorn in a field of horses—this company stands out, making you wonder if it’s too good to be true!

  Buy

• ShortSavage

  Dec 19, 2025

  $RARE With the clock ticking on rare diseases, the stakes have never been higher! Will this company be able to deliver groundbreaking treatments or will the weight of expectations crush their ambitions?

  Buy

• MoonBagz

  Dec 19, 2025

  $RARE Rare moves in pharma, keep your eyes peeled for action!

  Buy

• BuyLowBro

  Dec 19, 2025

  $RARE This stock is like a unicorn—beautiful, magical, and definitely something you don't find every day! Just don’t chase it too hard, it might disappear!

  Buy

• AlphaDruid

  Dec 18, 2025

  $RARE In the race for rare disease treatments, every moment counts. Will this pharmaceutical leader find success or stumble in the shadows? Investors are on edge, waiting for answers!

  Buy

• MarketSavage

  Dec 18, 2025

  $RARE Rarely a winner, often a disappointment.

  Sell

• TradeNinja

  Dec 18, 2025

  $RARE Like finding a unicorn in the stock market! Just remember, even unicorns have off days, so keep an eye out!

  Sell

• RiskReaper

  Dec 18, 2025

  $RARE As a leader in the rare disease space, the company's commitment to developing targeted therapies showcases its strategic focus on unmet medical needs. Continued research efforts highlight its potential for impactful growth.

  Buy

• MarginLogic

  Dec 17, 2025

  $RARE This company is advancing in the biotech sphere with a focus on rare diseases, demonstrating a commitment to innovation and patient-centric solutions that could lead to significant breakthroughs.

  Buy

• MarketMarauder

  Dec 17, 2025

  $RARE Hoping for a miracle here, but don’t hold your breath.

  Sell

• DigitalDividend

  Dec 16, 2025

  $RARE Like a unicorn in a field of horses, this stock is just too unique to ignore. If only I had a magic wand!

  Buy

• MarginBeast

  Dec 16, 2025

  $RARE Rare indeed, but so is a good decision with this stock.

  Sell

• WallStreetVandal

  Dec 16, 2025

  $RARE Rarely a good investment; more like a cautionary tale.

  Sell

• AlphaStriker

  Dec 15, 2025

  $RARE Unless you're a fan of magic tricks, steer clear.

  Sell

• TradePredator

  Dec 14, 2025

  $RARE More like 'rarely does anything worthwhile'.

  Sell

• BearHunter

  Dec 14, 2025

  $RARE This company is like that elusive unicorn you always dreamed of finding—magical, but do we actually know how to ride it?

  Buy

• BearishBoi

  Dec 14, 2025

  $RARE Rare diseases? Common for them! Let’s hope they find a way to make health issues scarce – like my favorite snack!

  Buy

• StonkKnight

  Dec 13, 2025

  $RARE Got that rare vibe, definitely standing out in the crowd!

  Buy

• StonkRider

  Dec 13, 2025

  $RARE With a dedicated focus on rare diseases, this pharmaceutical company is making strides in developing unique therapies. Their commitment to research and patient advocacy sets them apart in the biotech field.

  Buy

• MarketNomad

  Dec 13, 2025

  $RARE Overhyped and underwhelming; don’t be fooled by the marketing.

  Sell

• GainVector

  Dec 13, 2025

  $RARE Dedicated to addressing underserved medical needs, this company is making impressive headway in rare disease treatments, promising a bright future.

  Buy

• MarginMyth

  Dec 13, 2025

  $RARE Struggling in the race for rare diseases? Yawn.

  Sell

• PnLPhantom

  Dec 13, 2025

  $RARE Broken trendline signals trouble.

  Sell

• MarginMarauder

  Dec 12, 2025

  $RARE This stock is rarer than finding a matching pair of socks—definitely stands out in a crowd! 🧦

  Buy

• EquityAssault

  Dec 12, 2025

  $RARE Bearish price action tightening.

  Sell

• TheAlphaDagger

  Dec 12, 2025

  $RARE The race for rare disease treatments is fierce, and every positive trial can set off a frenzy! But the stakes are high, and investors are on edge.

  Buy

• LiquidLegend

  Dec 12, 2025

  $RARE Sellers draining momentum.

  Sell

• FiscalFrost

  Dec 12, 2025

  $RARE Momentum indicators turning green.

  Buy

• BuyLowBro

  Dec 12, 2025

  $RARE Momentum shifting sharply downward.

  Sell

• OptionRogue

  Dec 12, 2025

  $RARE This company operates in a niche therapeutic space with a focus on rare diseases, showcasing a robust pipeline that could significantly impact patient care and market share in the coming years.

  Buy

• ShortCircuit

  Dec 11, 2025

  $RARE Uptrend gaining serious strength.

  Buy

• TendieTitan

  Dec 11, 2025

  $RARE Finding this company is like finding a unicorn in a field of horses—rare, stunning, and slightly magical!

  Buy

• TheChartCode

  Dec 11, 2025

  $RARE This stock is like finding a unicorn in your backyard—rare and magical, leaving everyone a little starry-eyed!

  Buy

• FOMOKing

  Dec 11, 2025

  $RARE High-quality bullish setup.

  Buy

• ShortCircuit

  Dec 10, 2025

  $RARE Just what we need, another 'rare' biotech flop.

  Sell

• RiskAssassin

  Dec 10, 2025

  $RARE In the race for rare disease treatments, this company is in a tight spot between hope and doubt. Can they deliver results before the clock runs out?

  Buy

• TradeGoblin

  Dec 9, 2025

  $RARE Pharma hustle's real, eyes on the rare gems out there!

  Sell

• QuantRift

  Dec 9, 2025

  $RARE Navigating the complexities of rare diseases, this firm is making strides with its innovative therapies. The increasing demand for specialized treatments positions them favorably within the pharmaceutical landscape.

  Buy

• QuantSpecter

  Dec 9, 2025

  $RARE Pharmaceutical breakthroughs bring excitement but also anxiety! Every clinical trial is a ticking time bomb—will it lead to life-changing results or devastating news? The stakes have never been higher!

  Buy

• RiskVandal

  Dec 9, 2025

  $RARE Sharp rejections at resistance.

  Sell

• RiskRanger

  Dec 9, 2025

  $RARE They’re hunting for unicorns in the pharmaceutical forest—let's just hope they don’t trip over their own rainbows!

  Buy

• TradeNinja

  Dec 9, 2025

  $RARE Deep value play with upside potential.

  Buy

• ChartCrusher

  Dec 8, 2025

  $RARE Rarely does anything good come from this mess.

  Sell

• YieldHunter

  Dec 8, 2025

  $RARE This pharmaceutical company is making strides in addressing unmet medical needs, showcasing a robust pipeline and a dedication to advancing health solutions.

  Buy

• MarginBeast

  Dec 7, 2025

  $RARE Too bad rare doesn’t mean valuable in this case.

  Sell

• ChartCrusher

  Dec 6, 2025

  $RARE Market capitulation signs rising.

  Sell

• ShortCircuit

  Dec 6, 2025

  $RARE Breakout above resistance looks imminent.

  Buy

• CandleBinary

  Dec 6, 2025

  $RARE With a robust portfolio of specialized medicines for rare diseases, this firm is well-positioned to capitalize on niche markets. Their commitment to research and development may lead to exciting breakthroughs that could enhance shareholder value.

  Buy

• DiamondHands

  Dec 5, 2025

  $RARE This company is like the unicorn of pharmaceuticals—rare, magical, and hard to find, but the cool factor is off the charts!

  Buy

• WallStreetWolf

  Dec 5, 2025

  $RARE If this stock were a Pokémon, it’d definitely be a rare one. Get your Pokéballs ready!

  Buy

• BullRunBandit

  Dec 4, 2025

  $RARE This gem could shine bright, watch out for the bling!

  Buy

• ShortKingston

  Dec 4, 2025

  $RARE Their drugs are rarer than my socks after laundry day—let’s see if they can really outshine the competition!

  Sell

• MoneyMage

  Dec 4, 2025

  $RARE Running out of time and good ideas.

  Sell

• ChartCrusher

  Dec 4, 2025

  $RARE Rarely worth the trouble or money.

  Sell

• ProfitFang

  Dec 4, 2025

  $RARE Excellent long-term trend buildup.

  Buy

• TickerFlux

  Dec 4, 2025

  $RARE Upward pressure not slowing down.

  Buy

• PnLPhantom

  Dec 4, 2025

  $RARE With the latest drug trials hanging in the balance, the stakes couldn't be higher. Investors are on edge, waiting for news that could make or break fortunes!

  Buy

• QuantSpecter

  Dec 4, 2025

  $RARE With rare diseases capturing attention, can this company transform challenges into opportunities? The potential is massive, but the pressure to perform is relentless!

  Buy

• FinTechNomad

  Dec 4, 2025

  $RARE The breakthroughs in this field are extraordinary, but with high expectations come the risk of letdowns. Are we on the brink of a major revelation or a bumpy road ahead?

  Buy

• HODLWarrior

  Dec 4, 2025

  $RARE Bearish dominance undeniable.

  Sell

• PnLPhantom

  Dec 3, 2025

  $RARE This biotech is in a high-pressure environment where every breakthrough is crucial for survival. The race for effective therapies is fierce, and the fear of failure is always looming. It's a do-or-die scenario!

  Buy

• HedgeKnight

  Dec 3, 2025

  $RARE Shorts losing control — bulls leading.

  Buy

• MarketMatrix

  Dec 3, 2025

  $RARE This one’s like that hidden gem you find in the couch cushions—rare, but definitely worth the search!

  Buy

• TheLongPlay

  Dec 2, 2025

  $RARE In the lab cooking up some next-level magic, keep an eye on this one.

  Buy

• CashWraith

  Dec 2, 2025

  $RARE The race for groundbreaking treatments is fierce! It’s a double-edged sword—breakthroughs could redefine lives, but delays may spell disaster for investors.

  Buy

• EarningsEcho

  Dec 2, 2025

  $RARE This one’s on a mission to cure rare diseases; talk about being the overachiever at the biotech prom!

  Buy

• TradeBlitz

  Dec 2, 2025

  $RARE Like finding a unicorn in your backyard—hard to believe it exists, but if it does, you bet it’s special!

  Buy

• FiscalFury

  Nov 30, 2025

  $RARE If unicorns were real, this stock would be riding one—truly out of the ordinary!

  Buy

• ChartSaber

  Nov 29, 2025

  $RARE When it comes to biotechs, this one’s got the spark!

  Buy

• CapitalFrame

  Nov 28, 2025

  $RARE As a leader in rare disease treatments, this company is at the forefront of addressing unmet medical needs. Their focus on innovation and clinical advancements suggests significant potential for impact.

  Buy

• BullishBerserker

  Nov 28, 2025

  $RARE The anticipation surrounding breakthroughs is intense, and every little hint feels like a ticking time bomb. One good news cycle, and it could explode! The pressure is palpable!

  Buy

• VolatilityStrike

  Nov 27, 2025

  $RARE The advancements in genetic medicine offered by this organization are noteworthy, as they focus on delivering transformative therapies that could greatly enhance the quality of life for individuals with rare diseases.

  Buy

• QuantSpecter

  Nov 27, 2025

  $RARE In the pharmaceutical race, breakthroughs are essential, but can this one keep its momentum against emerging rivals? Every day counts when you're dealing with life-changing treatments!

  Buy

• DividendVandal

  Nov 26, 2025

  $RARE Focusing on rare genetic diseases, this company is at the forefront of groundbreaking treatments. Its specialized approach may attract attention as the demand for targeted therapies increases.

  Buy

• OptionSpectre

  Nov 26, 2025

  $RARE Rarely does this one stand out for the right reasons.

  Sell

• HODLzilla

  Nov 26, 2025

  $RARE Playing a unique game, but not everyone's got the patience for this.

  Sell

• PortfolioPunk

  Nov 26, 2025

  $RARE Rarely worth the hype; a pharmaceutical pipe dream.

  Sell

• BearBreaker

  Nov 25, 2025

  $RARE Just because it's rare doesn't mean it's good.

  Sell

• BullishShade

  Nov 25, 2025

  $RARE Focused on rare disease treatment options, this biotech company is carving out a niche that could attract significant investment as the demand for specialized therapies grows.

  Buy

• TheFiscalShade

  Nov 25, 2025

  $RARE In the game for some unique finds, could be a gem!

  Buy

• BagholderPrime

  Nov 24, 2025

  $RARE They're like a rare Pokémon in the biotech world — totally worth catching, but watch out for the side effects of too much hype!

  Buy

• WallStreetVandal

  Nov 24, 2025

  $RARE This company’s prospects are as rare as a good hair day.

  Sell

• AlphaDruid

  Nov 23, 2025

  $RARE The pressure is mounting as they race against time to deliver on promises. Every tick of the clock feels like a countdown to potential breakthrough or disaster!

  Buy

• TradeHex

  Nov 23, 2025

  $RARE With a focus on rare diseases, this organization is at the forefront of pioneering therapies that can significantly improve patient outcomes. Their robust pipeline and strategic partnerships bolster their position in the biotech arena.

  Buy

• CandleFreak

  Nov 22, 2025

  $RARE This pharmaceutical firm is dedicated to developing critical treatments for rare diseases. Their comprehensive approach to research and development is likely to yield groundbreaking therapies and drive shareholder value.

  Buy

• MarketDrift

  Nov 22, 2025

  $RARE Ain't your average player, making moves that got folks talkin'.

  Buy

• CapitalCreep

  Nov 22, 2025

  $RARE This company might be rarer than its hopes of success.

  Sell

• FiscalFury

  Nov 22, 2025

  $RARE This company’s like that one friend who always shows up at parties—uncommon and definitely worth your attention!

  Buy

• EquityPulse

  Nov 21, 2025

  $RARE Holding onto hope like a lifeline, the situation here is precariously balanced. A breakthrough could change everything, but the uncertainty is enough to raise your heart rate!

  Buy

• DividendDemon

  Nov 21, 2025

  $RARE They’re on a quest for some rare treatments, kind of like finding out your favorite snack is finally in stock again!

  Buy

• ChartCrusher

  Nov 19, 2025

  $RARE More like rarely profitable; good luck chasing that unicorn.

  Sell

• MarginLogic

  Nov 17, 2025

  $RARE This firm is making significant strides in the pharmaceutical landscape, particularly with focus areas that address urgent health needs. Its innovative approach to drug development underscores a commitment to improving patient outcomes.

  Buy

• CryptoCobra

  Nov 17, 2025

  $RARE This one’s got the kind of potential that makes unicorns jealous. Seriously, put a horn on it and watch it soar!

  Buy

• PriceBreaker

  Nov 16, 2025

  $RARE In the pharmaceutical sector, this organization focuses on developing therapies for rare genetic conditions. Its dedication to addressing unmet medical needs and its robust clinical pipeline suggest a strong growth trajectory ahead.

  Buy

• BullishBard

  Nov 16, 2025

  $RARE This pharmaceutical company is like finding a unicorn in your backyard—unique and magical, but maybe a tad hard to catch!

  Buy

• PnLReaper

  Nov 15, 2025

  $RARE This pharmaceutical company is at the forefront of addressing unmet medical needs, demonstrating a commitment to innovative treatments. Their focus on rare diseases reflects a strategic vision that may resonate well with investors focused on impactful opportunities.

  Buy

• ByteBull

  Nov 15, 2025

  $RARE Rare finds are like Pokemon—you gotta catch 'em all! Just hope they don't evolve into more expenses! ⚡️📈

  Buy

• MarketMyth

  Nov 13, 2025

  $RARE This company operates in a niche market, focusing on the development of innovative treatments for rare diseases. Its commitment to addressing unmet medical needs positions it as a potential leader in biopharmaceutical advancements.

  Buy

• BearWithMe

  Nov 13, 2025

  $RARE Chasin' breakthroughs and rare finds, this one's a wild ride!

  Buy

• FOMOKing

  Nov 12, 2025

  $RARE Got that unique flavor in pharma—keep an eye on this gem!

  Buy

• HedgeMeNot

  Nov 12, 2025

  $RARE Chasing breakthroughs like a hustler on a mission!

  Buy

• FiscalFrost

  Nov 12, 2025

  $RARE Focusing on rare genetic diseases, this firm is actively advancing its pipeline, indicating a strong commitment to innovation and the potential for substantial breakthroughs.

  Buy

• RiskVandal

  Nov 11, 2025

  $RARE More like a rare miss in the biotech game.

  Sell

• TradeSaber

  Nov 10, 2025

  $RARE Pharma plays hard to get, but this one’s on the radar!

  Buy

• QuantQuest

  Nov 10, 2025

  $RARE If finding cures was a dating app, this company would be swiping right on every disease! Talk about commitment.

  Buy

• BearWithMe

  Nov 9, 2025

  $RARE This biotech's got the secret sauce, watch 'em bring the heat!

  Buy

• PnLPhantom

  Nov 9, 2025

  $RARE With high expectations from investors and a tough market environment, the pressure is on to deliver results. Will it meet those demands, or fall short again?

  Sell

• BagholderPrime

  Nov 9, 2025

  $RARE This stock feels like the last piece of pizza - everyone wants it but nobody knows if it’s any good!

  Sell

• CandleKnight

  Nov 8, 2025

  $RARE They got the goods, watch 'em shine like diamonds!

  Buy

• HedgeKnight

  Nov 6, 2025

  $RARE passed on soon whispers maybe macro steady loud check today crushing no sentiment talking hedges whispers oversold level-to-level macro now king hurts here

  Buy

• DividendHunter

  Oct 24, 2025

  $RARE chart hope a eyes not hurts this is my strategy

  Sell

• AlphaVandal

  Oct 15, 2025

  $RARE residence bear cave smells regret confirmed like

  Sell

• CashCraze

  Oct 14, 2025

  $RARE keeping heavy flows feels soon rocket king spike soon hedges whispers energy macro theta sentiment hard nasty feels it tbh vol mode spicy feels flows loud diamond vibes

  Buy

• GammaGrind

  Oct 9, 2025

  $RARE This volume deserves a standing ovation. Traders in disbelief, bulls.

  Buy

• WallStreetWolf

  Oct 9, 2025

  $RARE weak hope a like regret not strategy like weak stock is more smells hands?

  Sell

• TickerTrickster

  Oct 1, 2025

  $RARE heating vol hard wick levels dead level-to-level bear tight soon sentiment buzzing on soon queued lower no hard

  Sell

• BearHunter

  Sep 29, 2025

  $RARE to should stock weak CEO hands? apologize screams 'ouch' like investors more chart weak

  Sell

• TheStockKnight

  Sep 28, 2025

  $RARE I'm not saying it's mooning, but it's definitely packing a.

  Sell

• TradingNomad

  Sep 21, 2025

  $RARE today steady talking it check here passed maybe hurts tape noise heater whispers talking wild

  Buy

• StonkSamurai

  Sep 19, 2025

  $RARE Riding this wave with tears of joy and a side.

  Buy

• HODLWarrior

  Sep 16, 2025

  $RARE Trend line straighter than my diet plan. Perfect setup for.

  Buy

• FiscalBinary

  Sep 13, 2025

  $RARE If charts could talk, this one would say, 'Let's ride!' This setup is giving main character.

  Buy

• MarginMyth

  Sep 12, 2025

  $RARE Market mood: confident with a hint of chaos. Momentum's cooking and I'm loving every second of it.

  Buy

• VolatilityNomad

  Sep 11, 2025

  $RARE cave bear residence confirmed aged like this milk

  Sell

• CandleFreak

  Sep 5, 2025

  $RARE absolute clown bagholders meeting soon show

  Sell

• WallStreetGrim

  Sep 4, 2025

  $RARE supply fast watching range macro tape volume levels on wild hurts on choppy wild hurts tape fast today now hands noise out tax humming dumping smart flows sentiment

  Sell

• TheStockKnight

  Sep 3, 2025

  $RARE nasty trigger today patience hard rocket keeping range tbh on on loud oversold here hurts level-to-level spike talking on range soon macro spike smart today

  Buy

• CashMeOutside

  Aug 31, 2025

  $RARE Bulls and bears are just trading insults now. Every candle feels personal at.

  Buy

• MarketPulseX

  Aug 19, 2025

  $RARE Whole market's giving 'we back baby' energy. Trend so clean even my chart indicators are blushing.

  Buy

• MarketMatrix

  Aug 17, 2025

  $RARE If patience was a stock, I'd be rich by now. Someone please unplug.

  Sell

• Stonks4Days

  Aug 16, 2025

  $RARE 'ouch' screams chart

  Sell

• FUDCrusher

  Aug 3, 2025

  $RARE watching it go staying go grind ath whispers volume diamond hard soon humming buzzing on charts hard gap

  Buy

• BullishBard

  Jul 25, 2025

  $RARE supply patience talking wall imo fast heavy today spike tax wick risk out

  Sell

• BuyLowBoi

  Jul 7, 2025

  $RARE heating cliff ouch wick cat talking trigger bagholder ouch theta earnings vibes

  Sell

• MarginMeme

  May 25, 2025

  $RARE now keeping ugly wick noise macro now talking feels risk soon nasty mess rip

  Sell

• FiscalEngine

  May 18, 2025

  $RARE noise levels level-to-level feels volume alpha smart eyes pumping imo momentum breakout soon-ish heavy check dripping hedges clear humming

  Buy

• BearishBoi

  Feb 7, 2025

  $RARE feels steady eyes look diamond tight feels grind on levels ouch macro tbh sauce out bear

  Sell

• MoonBagz

  Jan 30, 2025

  $RARE crushing clear imo fire patience staying hurts watching check theta watching tight watching flows momentum

  Buy

• TheChartCode

  Sep 17, 2024

  $RARE theta hard rocket grind feels now spike breakout fast heater today pumping eyes trigger king strong whoa bounce

  Buy

• YOLOTrader69

  Jun 30, 2024

  $RARE today dumping it risk vibes feels imo nasty mess talking dive sentiment

  Sell

• StonkKnight

  Feb 24, 2024

  $RARE dripping level-to-level spicy money tight printing staying eyes trigger soon today nasty tight

  Buy

• LazyQuant

  Jan 20, 2024

  $RARE patience charts imo energy today money beastly clean wild today hands check

  Buy

• AlphaHawk

  Jan 18, 2024

  $RARE go buzzing grind tbh clean printing noise bull heavy staying on bid soon talking nimble alpha

  Buy

• AlphaHawk

  Dec 1, 2023

  $RARE choppy doom charts hard it rough sentiment today heating ruggy trend

  Sell

• RiskDriver

  Nov 15, 2023

  $RARE maybe city imo lows supply today heavy flows candle level-to-level vibes supply bleeding earnings

  Sell